Lupus & antiphospholipid syndrome
Patient-reported disease impact of systemic lupus erythematosus with active joint symptoms: Results from the systemic lupus erythematosus-update survey
Authors' conclusion
Respondents with SLE and active joint manifestations in addition to having more pain report lower HRQoL and were less satisfied with their current treatments.
Study context
- Population
- Adults with systemic lupus erythematosus (SLE), 2019 US survey (SLE-UPDATE)
- Participants
- 285 vs 215
- Exposure
- Active joint symptoms vs no currently active joint symptoms
- Active jointn = 285
- Non-active jointn = 215reference
- Outcome
- Pain most or all the time over the preceding 7 days
- Follow-up
- Preceding 7 days
Methodological detailssurvey
- Survey
Main finding
As reported in the abstract
P < 0.0001
Observational data: associations, not effects.
Further findings
Fibromyalgia
P < 0.0001
Neutral or not satisfied with current treatments and rated reducing pain a "very important" treatment goal
Mean
| Outcome | Active joint | Non-active joint | P value |
|---|---|---|---|
| Worst Pain NRS (higher worse) | 6.5 | 4.8 | P < 0.0001 |
| Worst Joint Pain NRS (higher worse) | 6.7 | 4.5 | P < 0.0001 |
| LupusPRO HRQoL total score (lower worse) | 48.9 | 64.1 | P < 0.0001 |
WPAI-Lupus work productivity loss and activity impairment
- Greater work productivity losses and activity impairment in the active joint cohort
Original publication
Patient-reported disease impact of systemic lupus erythematosus with active joint symptoms: Results from the systemic lupus erythematosus-update survey. Lupus. Published 21 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →